相关实验视频

Updated: May 9, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

[检测前列腺癌需要多少MRI序列?]

Fabian Falkenbach^1,2, Tim Inderhees¹, Lars Budäus^1,3

¹Martini-Klinik Prostatakarzinomzentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.

Aktuelle Urologie

|May 5, 2025

概括

没有对比度增强的双参数MRI (bpMRI) 建议用于早期前列腺癌检测,因为与多参数MRI (mpMRI) 相比,效果相似,成本降低. 动态对比增强 (DCE) 核磁共振可能只适用于特定复杂的病例.

科学领域:

放射学放射学是指放射学
在瘤学瘤学.
医疗成像医学成像

背景情况:

多参数MRI (mpMRI) 结合了解剖学,扩散权重 (DWI) 和对比增强 (DCE) 序列来评估前列腺癌.
DWI评估水分子运动的组织组成,而DCE评估 perfusion 和血管生成.

研究的目的:

评估双参数MRI (bpMRI) 与mpMRI在早期前列腺癌检测中的作用.
确定DCE序列是否对所有前列腺癌评估至关重要.

主要方法:

对临床显著前列腺癌的bpMRI (没有DCE的MRI) 和mpMRI之间的检测率的比较.
分析特定场景,在这些场景中,将DCE添加到bpMRI可能是有益的.

主要成果:

与mpMRI相比,bpMRI显示了临床显著前列腺癌的可比检测率.
没有DCE的MRI查更安全,更具成本效益,并减少了加多暴露.

结论:

应将bpMRI视为早期前列腺癌检测的标准.
DCE 序列可以保留用于特定的指示,如治疗后评估或在负面bpMRI后持续的怀疑.

更多相关视频

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

相关概念视频

Magnetic Resonance Imaging

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...